Please login to the form below
carflizomib
This page shows the latest carflizomib news and features for those working in and with pharma, biotech and healthcare.
NICE set to knock-back Amgen's myeloma treatment Kyprolis
NICE's draft guidance is part of its assessment for NHS use of Kyprolis (carflizomib) in combination with Celgene's Revlimid (lenalidomide) and dexamethasone to treat adults who have received at
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Director, Healthcare Communications
-
Salary TBC
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
-
Account Director – UK Office
-
Excellent salary and benefits
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
Subscribe to our email news alerts
- Blended Intelligence
- Planning a pharma exhibition stand? You must read this!
- Leaked no-deal Brexit document forecasts widespread shortages
- AbbVie scores FDA approval for arthritis treatment upadacitinib
- Novo Nordisk shareholder revolt reaches Europe
- BMS buoyed by FDA approval of Celgene’s myelofibrosis drug
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
- The evolution of real-world studies
- How industry and regulators are using real-world data...
Quick links
Infographics
